Jodie Morrison

Chief Executive Officer

Jodie Morrison is the Chief Executive Officer of Cadent Therapeutics and is a member of Cadent’s Board of Directors. Ms. Morrison most recently served as interim Chief Executive Officer at Keryx Biopharmaceuticals, Inc.  Previously she served as President and Chief Executive Officer of Tokai Pharmaceuticals, Inc. Prior to being appointed President and Chief Executive Officer at Tokai, Ms. Morrison held other senior positions with the company, including Chief Operating Officer, Head of Clinical Affairs and Program Operations, and Vice President of Clinical Affairs and Program Operations. Prior to joining Tokai, Ms. Morrison held roles in clinical operations and medical affairs at Dyax Corporation, Curis, Inc., and Diacrin, Inc. Ms. Morrison currently sits on the Board of Directors for Akebia Therapeutics (AKBA) and Aileron Therapeutics (ALRN).

Ms. Morrison received a B.A. in neuroscience from Mount Holyoke College, her clinical research certification from Boston University School of Medicine, and her business training through the Greater Boston Executive Program at the MIT Sloan School of Management.

Our Team

Jodie Morrison

Chief Executive Officer

Jodie Morrison is the Chief Executive Officer of Cadent Therapeutics and is a member of Cadent’s Board of Directors. Ms. Morrison most recently served as interim Chief Executive Officer at Keryx Biopharmaceuticals, Inc.  Previously she served as President and Chief Executive Officer of Tokai Pharmaceuticals, Inc. Prior to being appointed President and Chief Executive Officer at Tokai, Ms. Morrison held other senior positions with the company, including Chief Operating Officer, Head of Clinical Affairs and Program Operations, and Vice President of Clinical Affairs and Program Operations. Prior to joining Tokai, Ms. Morrison held roles in clinical operations and medical affairs at Dyax Corporation, Curis, Inc., and Diacrin, Inc. Ms. Morrison currently sits on the Board of Directors for Akebia Therapeutics (AKBA) and Aileron Therapeutics (ALRN).

Ms. Morrison received a B.A. in neuroscience from Mount Holyoke College, her clinical research certification from Boston University School of Medicine, and her business training through the Greater Boston Executive Program at the MIT Sloan School of Management.

Our Team

Jodie Morrison

Chief Executive Officer

Jodie Morrison is the Chief Executive Officer of Cadent Therapeutics and is a member of Cadent’s Board of Directors. Ms. Morrison most recently served as interim Chief Executive Officer at Keryx Biopharmaceuticals, Inc.  Previously she served as President and Chief Executive Officer of Tokai Pharmaceuticals, Inc. Prior to being appointed President and Chief Executive Officer at Tokai, Ms. Morrison held other senior positions with the company, including Chief Operating Officer, Head of Clinical Affairs and Program Operations, and Vice President of Clinical Affairs and Program Operations. Prior to joining Tokai, Ms. Morrison held roles in clinical operations and medical affairs at Dyax Corporation, Curis, Inc., and Diacrin, Inc. Ms. Morrison currently sits on the Board of Directors for Akebia Therapeutics (AKBA) and Aileron Therapeutics (ALRN).

Ms. Morrison received a B.A. in neuroscience from Mount Holyoke College, her clinical research certification from Boston University School of Medicine, and her business training through the Greater Boston Executive Program at the MIT Sloan School of Management.

Our Team